Not So Different: A Podcast from The Center for Biosimilars

S6 Ep14: Biosimilars Immunology Roundup for July 2023- Podcast Edition

Listen

Description


Show Notes



First Round of Adalimumab Biosimilar Launches in July



Celltrion Launches Yuflyma on the US Market



US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market



Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending?



Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?



Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price



Price Reductions of TNF Inhibitors Across Europe After First and Second Biosimilar Launches



Multiple Infliximab Biosimilar Switches Were Safe, Effective



Adalimumab Biosimilar Improved Symptoms for up to 48 Weeks in Ankylosing Spondylitis



Biosimilar, Innovator Romiplostim Comparably Safe and Effective